‘Obesity surgery’ is good… Compared to taking medication, the risk of kidney disease worsening is reduced by 60%, and the risk of death from kidney failure progression is reduced by 44%
A feared complication for obese diabetics is chronic kidney disease (kidney disease). Some chronic kidney disease patients need hemodialysis three times a week to remove waste products from the blood.
A study found that bariatric surgery is much more effective than simply taking medication to protect the kidneys of obese type 2 diabetic patients from chronic kidney disease complications and prevent kidney function from declining. The Cleveland Clinic research team in the United States announced the results of an eight-year clinical study of 425 patients aged 18 to 75 with obese type 2 diabetes and stage 3 to 4 chronic kidney disease.
According to the study, obese diabetic patients with chronic kidney disease as a complication had a 60% lower risk of kidney disease progression (worsening) when they underwent bariatric surgery compared to those treated with medication (GLP-1 receptor agonists). In particular, the risk of kidney disease progressing to dangerous kidney failure and the risk of death due to it were found to be reduced by 44%. Among patients who underwent bariatric surgery, 22% experienced kidney disease progression to kidney failure, while among patients who received medication, 45% experienced kidney disease progression to kidney failure.
Twenty-four percent of the surgical group developed or died of renal failure, compared with 44 percent of the nonsurgical drug group. Patients who underwent bariatric surgery also needed to reduce the amount of medication they needed to control their diabetes, high blood pressure, and high cholesterol.
Of the patients in the study, 183 underwent bariatric surgery and 242 received drug treatment. These patients either underwent bariatric surgery between 2010 and 2017 or continued to receive drugs (GLP-1 receptor agonists) during the study period. During the follow-up period, 20% of the patients in the non-surgical/drug group received drugs such as semaglutide (brand name Ozempic) or tirzepatide (brand name Mounzaro) at some point.
According to the Centers for Disease Control and Prevention (CDC), more than one in seven American adults is estimated to have chronic kidney disease, which can lead to kidney failure. The kidneys filter waste products from the blood, but when they start to lose function, waste products build up.
“Even obese diabetic patients with chronic kidney disease can change their disease trajectory with bariatric surgery,” said study lead author Dr. Ali Aminian, director of the Obesity and Metabolism Research Institute. “Bariatric surgery is underutilized in clinical practice, but it should be considered as a treatment option for patients with chronic kidney disease and obesity.”
The results of this study (Renoprotective Effects of Metabolic Surgery Versus GLP1 Receptor Agonists on Progression of Kidney Impairment in Patients with Established Kidney Disease) were published in the Annals of Surgery.
Source: kormedi.com
